Published in Front Immunol on October 10, 2016
In Vitro and In Vivo Differences in Murine Third Complement Component (C3) Opsonization and Macrophage/Leukocyte Responses to Antibody-Functionalized Iron Oxide Nanoworms. Front Immunol (2017) 0.75
Iron oxide nanoparticles induce cytokine secretion in a complement-dependent manner in a human whole blood model. Int J Nanomedicine (2017) 0.75
Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials (2005) 11.01
Complement: a key system for immune surveillance and homeostasis. Nat Immunol (2010) 10.37
Macrophage receptors and immune recognition. Annu Rev Immunol (2005) 5.83
Biodegradable luminescent porous silicon nanoparticles for in vivo applications. Nat Mater (2009) 4.77
CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. Cell (2006) 2.89
Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting. Small (2009) 2.16
Immunospecific ferromagnetic iron-dextran reagents for the labeling and magnetic separation of cells. J Immunol Methods (1982) 2.16
Magnetic Iron Oxide Nanoworms for Tumor Targeting and Imaging. Adv Mater (2008) 2.01
Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly. J Immunol (2007) 2.00
Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles. Nanomedicine (2008) 1.99
Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology (2005) 1.95
Uptake of dextran-coated monocrystalline iron oxides in tumor cells and macrophages. J Magn Reson Imaging (1998) 1.77
The alternative pathway of complement in disease: opportunities for therapeutic targeting. Mol Immunol (2004) 1.40
Immunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups. Biomaterials (2009) 1.35
Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J Control Release (2007) 1.27
The role of anaphylatoxins C3a and C5a in regulating innate and adaptive immune responses. Inflamm Allergy Drug Targets (2009) 1.22
Variable antibody-dependent activation of complement by functionalized phospholipid nanoparticle surfaces. J Biol Chem (2010) 1.20
Differential proteomics analysis of the surface heterogeneity of dextran iron oxide nanoparticles and the implications for their in vivo clearance. Biomaterials (2009) 1.19
Complement and its receptors: new insights into human disease. Annu Rev Immunol (2014) 1.17
Interactions of blood proteins with poly(isobutylcyanoacrylate) nanoparticles decorated with a polysaccharidic brush. Biomaterials (2005) 1.14
The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb). Mol Immunol (2007) 1.14
C3 adsorbed to a polymer surface can form an initiating alternative pathway convertase. J Immunol (2002) 1.13
Influence of polysaccharide coating on the interactions of nanoparticles with biological systems. Biomaterials (2006) 1.12
Liposome-complement interactions in rat serum: implications for liposome survival studies. Biochim Biophys Acta (1994) 1.10
Activation of human complement by liposomes: a model for membrane activation of the alternative pathway. J Immunol (1979) 1.08
Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Mol Immunol (2008) 1.06
Preparing serum for functional complement assays. J Immunol Methods (2009) 1.04
Complement activation by core-shell poly(isobutylcyanoacrylate)-polysaccharide nanoparticles: influences of surface morphology, length, and type of polysaccharide. Pharm Res (2006) 1.02
Inhibition of complement alternative pathway function with anti-properdin monoclonal antibodies. Mol Immunol (2000) 1.02
Single-walled carbon nanotube surface control of complement recognition and activation. ACS Nano (2013) 0.99
Complement consumption by poly(ethylene glycol) in different conformations chemically coupled to poly(isobutyl 2-cyanoacrylate) nanoparticles. Life Sci (1997) 0.98
Complement: alive and kicking nanomedicines. J Biomed Nanotechnol (2009) 0.97
Protection of nonself surfaces from complement attack by factor H-binding peptides: implications for therapeutic medicine. J Immunol (2011) 0.96
A novel antibody against human properdin inhibits the alternative complement system and specifically detects properdin from blood samples. PLoS One (2014) 0.96
Regulation of the human alternative complement pathway: formation of a ternary complex between factor H, surface-bound C3b and chemical groups on nonactivating surfaces. Eur J Immunol (1989) 0.94
Manipulating the mediator: modulation of the alternative complement pathway C3 convertase in health, disease and therapy. Immunobiology (2012) 0.93
Lipid monolayer collapse and microbubble stability. Adv Colloid Interface Sci (2012) 0.89
Interactions of nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate) with the complement system. Life Sci (1998) 0.89
Association of hydrophobically-modified poly(ethylene glycol) with fusogenic liposomes. Biochim Biophys Acta (2003) 0.87
Curvature of synthetic and natural surfaces is an important target feature in classical pathway complement activation. J Immunol (2010) 0.87
Modulatory Role of Surface Coating of Superparamagnetic Iron Oxide Nanoworms in Complement Opsonization and Leukocyte Uptake. ACS Nano (2015) 0.87
Concentration dependent structural ordering of poloxamine 908 on polystyrene nanoparticles and their modulatory role on complement consumption. J Nanosci Nanotechnol (2006) 0.87
Complement activation by polymers carrying hydroxyl groups. ACS Appl Mater Interfaces (2009) 0.84
Different effect of hydrogelation on antifouling and circulation properties of dextran-iron oxide nanoparticles. Mol Pharm (2012) 0.84
Modern complement analysis. Clin Diagn Lab Immunol (2003) 0.83
High-relaxivity superparamagnetic iron oxide nanoworms with decreased immune recognition and long-circulating properties. ACS Nano (2014) 0.83
Regulation by sulphonate groups of complement activation induced by hydroxymethyl groups on polystyrene surfaces. Biomaterials (1993) 0.82
The ability of Sephadex to activate human complement is suppressed in specifically substituted functional Sephadex derivatives. Mol Immunol (1988) 0.82
Qualitative analysis of total complement activation by nanoparticles. Methods Mol Biol (2011) 0.81
Complement monitoring of Pluronic 127 gel and micelles: suppression of copolymer-mediated complement activation by elevated serum levels of HDL, LDL, and apolipoproteins AI and B-100. J Control Release (2013) 0.81
The role of serum complement on the organ distribution of intravenously administered poly (methyl methacrylate) nanoparticles: effects of pre-coating with plasma and with serum complement. Pharm Res (1996) 0.79